Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.7876
  • Today's Change0.003 / 0.38%
  • Shares traded27.00
  • 1 Year change-10.70%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 07:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

  • Revenue in HKD (TTM)33.94bn
  • Net income in HKD6.34bn
  • Incorporated1992
  • Employees23.50k
  • Location
    CSPC Pharmaceutical Group LtdNo. 226 Huanghe AvenueSHIJIAZHUANG 050035ChinaCHN
  • Phone+86 31 187037015
  • Fax+86 31 187039608
  • Websitehttps://www.cspc.com.hk/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.